22 results on '"Althaus, Karina"'
Search Results
2. No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination.
- Author
-
Uzun, Günalp, Althaus, Karina, and Bakchoul, Tamam
- Subjects
- *
IMMUNOGLOBULINS , *MEDICAL personnel , *VACCINATION - Abstract
The article presents Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOxl nCoV-19 Vaccination. Topics discussed include Vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome, is a rare but potentially fatal complication of vector-based severe acute respiratory syndrome coronavirus 2 vaccines; and the clinical picture and the serologic findings in patients with VITI resemble heparin-induced thrombocytopenia.
- Published
- 2021
- Full Text
- View/download PDF
3. Heparin-induced thrombocytopenia: Diagnostic challenges in intensive care patients especially with extracorporeal circulation.
- Author
-
Althaus, Karina, Straub, Andreas, Häberle, Helene, Rosenberger, Peter, Hidiatov, Oleg, Hammer, Stefanie, Nowak-Harnau, Stefanie, Enkel, Sigrid, Riessen, Reimer, and Bakchoul, Tamam
- Subjects
- *
INTENSIVE care patients , *ARTIFICIAL blood circulation , *EXTRACORPOREAL membrane oxygenation , *ENZYME-linked immunosorbent assay , *THROMBOCYTOPENIA - Abstract
Heparin-induced thrombocytopenia (HIT) is a serious drug induced reaction that may be associated with life threatening complications. Platelet-activating antibodies directed against platelet factor 4 (PF4)/heparin complexes cause the disease. The diagnosis of HIT is challenging, as thrombocytopenia is a frequent finding in intensive care (ICU) patient population, especially during extracorporeal membrane oxygenation. To investigate the performance of a diagnostic algorithm for HIT in ICU patients. ICU patients who developed thrombocytopenia or thrombosis under heparin treatment were included in this study. The pretest probability for HIT was estimated using the 4Ts-score and patient's sera were tested using two rapid immunoassays (RA) LFI-HIT and PaGIA (from Milenia Biotec and DiaMed), and within 72 h using the IgG enzyme immunoassay (EIA) from Hyphen and the heparin induced platelet activation assay (HIPA). 392 consecutive ICU patients with suspected HIT were enrolled in this study, of whom 83/392 (21.2%) patients had extracorporeal circulation. Sera from 120/392 (30.6%) and 98/392 (25.0%) patients revealed positive results in RA and IgG EIA, respectively. The HIPA test revealed heparin-dependent platelet activation in a total of 15/392 (3.8%) ICU patients (3 medical and 12 surgical patients). In addition, sera from 7 patients revealed indeterminate HIPA results, of whom 2 patients had a clinical course compatible with HIT. Data from our study confirm the high frequency of IgG PF4/heparin antibodies in ICU patients under unfractionated heparin and shows that the combination of 4Ts-score and RA does not reduce the laboratory overinvestigation for HIT in these patients. • Diagnostic approach for HIT in ICU – a challenge for clinicians and laboratories • Management and clinical course of 4 cases with uncertain HIT diagnosis • 83/392 included patients had extracorporeal circulation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Evaluation of a flow cytometer-based functional assay using platelet-rich plasma in the diagnosis of heparin-induced thrombocytopenia.
- Author
-
Althaus, Karina, Pelzl, Lisann, Hidiatov, Oleg, Amiral, Jean, Marini, Irene, and Bakchoul, Tamam
- Subjects
- *
PLATELET-rich plasma , *ENZYME-linked immunosorbent assay , *BLOOD platelet aggregation , *PLATELET function tests - Abstract
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4/heparin (PF4/hep)-complexes. The in vitro demonstration of PF4/hep antibodies using functional assays is essential for an optimal management of patients suspected to have HIT. However, conventional functional assays are technically challenging and limited to specialized laboratories. In contrast, flow cytometers are commonly used in routine laboratories. The aim of this study is to investigate the performance characteristics of a commercially available, flow cytometer based assay in the diagnosis of HIT. Sera of consecutive patients with suspected HIT were investigated using the Emo-test HIT Confirm® assay and compared to the standard method consisting of an IgG-specific enzyme immunoassay (EIA) for anti-PF4/hep antibodies and the heparin induced platelet aggregation (HIPA) test. 390 sera were included in the study, 164 sera tested IgG EIA-positive, of which 33 also tested HIPA-positive. No HIPA-positive samples were EIA-negative. In the Emo-test HIT Confirm® assay, 112 sera revealed positive results (%Hepla > 13); however, 51 (45.5%) were EIA-negative. Of the 33 HIPA-positive/EIA-positive HIT sera, 23 tested positive in the Emo-test HIT Confirm® assay, 2 gave ambiguous results, and 8 sera yielded false-negative results. Accordingly, the HIT Confirm® assay showed a sensitivity of 69.7% with a slightly better specificity of 75.4% compared to the EIA (sensitivity 100%, specificity 63.3%). An increase in diagnostic specificity for HIT to 85% was found when positive results were obtained in both the Emo-test HIT Confirm® assay and EIA. The Emo-Test HIT Confirm® assay may improve the specificity of laboratory investigations of HIT. However, the assay can only be recommended in combination with an immunoassay due to the high rate of false negativity. Our observation indicates a need to establish external quality assessment for functional assays to avoid such clinically relevant pitfalls. • The HIT Confirm® assay may improve the specificity of laboratory investigations of HIT. • However, the assay can only be recommended in combination with an immunoassaydue to the high rate of false negativity. • This indicates a need to establish external quality assessment for functional assays to avoid such relevant pitfalls. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Hypofibrinolysis in pediatric patients with veno-occlusive disease in hematopoietic stem cell transplantation.
- Author
-
Schneider, Veronika, Cabanillas Stanchi, Karin M., Althaus, Karina, Schober, Sarah, Michaelis, Sebastian, Seitz, Christian, Lang, Peter, Handgretinger, Rupert, Bakchoul, Tamam, Hammer, Stefanie, and Döring, Michaela
- Subjects
- *
HEPATIC veno-occlusive disease , *HEMATOPOIETIC stem cell transplantation , *CHILD patients - Abstract
Purpose: Veno-occlusive disease (VOD) is a serious complication of hematopoietic stem cell transplantation (HSCT) with a high incidence in pediatric patients. This study aimed to detect signs of hypofibrinolysis using thrombelastography. Methods: In this prospective single-center study, thrombelastographic measurements (EX and TPA tests) were taken during HSCT to detect signs of impaired coagulation, clot formation, or hypofibrinolysis. Results: Of 51 patients undergoing allogeneic and autologous HSCT, five (9.8%) developed VOD and received defibrotide treatment. Thrombelastography measurements were also obtained from 55 healthy children as a control group. The results show that clot lysis was prolonged in VOD patients compared to other HSCT patients and control group (lysis time, TPA test: day + 14 to + 21: VOD: 330 ± 67 s vs. HSCT: 246 ± 53 s; p = 0.0106; control: 234 ± 50 s; control vs. VOD: p = 0.0299). The maximum lysis was reduced in HSCT patients compared to controls (EX test: control: 8.3 ± 3.2%; HSCT: day 0 to + 6: 5.3 ± 2.6%, p < 0.0001; day + 7 to + 13: 3.9 ± 2.1%, p < 0.0001; day + 14 to d + 21: 4.1 ± 2.3%, p < 0.0001). Conclusion: These results suggest that HSCT patients exhibit reduced fibrinolytic capacities and patients diagnosed with VOD show signs of hypofibrinolysis. This prospective study shows that fibrinolysis can be assessed in a rapid and accessible way via thrombelastography. Thrombelastography might be a parameter to support the diagnosis of a VOD and to serve as a follow-up parameter after the diagnosis of a VOD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Flucloxacillin-induced immune thrombocytopenia.
- Author
-
Jatzlauk, Gregor, Althaus, Karina, Strobel, Ulrike, Kiefel, Volker, Wesche, Jan, Muehlenberg, Klaus, Greinacher, Andreas, and Bakchoul, Tamam
- Subjects
- *
DRUG side effects , *THROMBOCYTOPENIA treatment , *BETA lactam antibiotics , *BLOOD platelets , *SEROLOGY , *THERAPEUTICS , *THROMBOPENIC purpura diagnosis , *ANTIBIOTICS , *THROMBOPENIC purpura , *OXACILLIN - Abstract
Background: Drug-induced immune thrombocytopenia (DITP) is an adverse drug reaction associated with platelet (PLT) destruction by drug-dependent antibodies. Demonstration of drug-dependent PLT antibodies is often difficult and can only be rendered by extensive laboratory testing. In this report, we present the first serologically confirmed case of DITP caused by the antibiotic flucloxacillin.Case Report: A 68-year-old man developed severe thrombocytopenia that was first suspected to be related to heparin-induced thrombocytopenia. The absence of PLT-activating heparin-dependent antibodies and the abrupt decrease in PLT count to fewer than 20 × 10(9) /L raised the suspicion of DITP.Discussion: Flucloxacillin-dependent antibodies were detected in patient serum using whole PLT enzyme immunoassay and flow cytometry. The glycoprotein (GP) specificity was identified to be against GP IIb/IIIa complexes using the monoclonal antibody immobilization of PLT antigens assay. Interestingly, antibody binding was abolished when EDTA plasma was used and restored after adding calcium.Conclusion: In summary, DITP should be considered in cases of acute thrombocytopenia during treatment with flucloxacillin. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
- Author
-
Uzun, Günalp, Müller, Rebecca, Althaus, Karina, Becker, Matthias, Marsall, Patrick, Junker, Daniel, Nowak-Harnau, Stefanie, Schneiderhan-Marra, Nicole, Klüter, Harald, Schrezenmeier, Hubert, Bugert, Peter, and Bakchoul, Tamam
- Subjects
- *
CONVALESCENT plasma , *IMMUNOGLOBULINS , *FEVER , *COVID-19 , *LOGISTIC regression analysis , *BODY mass index - Abstract
COVID-19 convalescent plasma (CCP) with high neutralizing antibodies has been suggested in preventing disease progression in COVID-19. In this study, we investigated the relationship between clinical donor characteristics and neutralizing anti-SARS-CoV-2 antibodies in CCP donors. COVID-19 convalescent plasma donors were included into the study. Clinical parameters were recorded and anti-SARS-CoV-2 antibody levels (Spike Trimer, Receptor Binding Domain (RBD), S1, S2 and nucleocapsid protein) as well as ACE2 binding inhibition were measured. An ACE2 binding inhibition < 20% was defined as an inadequate neutralization capacity. Univariate and multivariable logistic regression analysis was used to detect the predictors of inadequate neutralization capacity. Ninety-one CCP donors (56 female; 61%) were analyzed. A robust correlation between all SARS-CoV-2 IgG antibodies and ACE2 binding inhibition, as well as a positive correlation between donor age, body mass index, and a negative correlation between time since symptom onset and antibody levels were found. We identified time since symptom onset, normal body mass index (BMI), and the absence of high fever as independent predictors of inadequate neutralization capacity. Gender, duration of symptoms, and number of symptoms were not associated with SARS-CoV-2 IgG antibody levels or neutralization. Neutralizing capacity was correlated with SARS-CoV-2 IgG antibodies and associated with time since symptom onset, BMI, and fever. These clinical parameters can be easily incorporated into the preselection of CCP donors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Living kidney donor evaluation is associated with early identification of life‐changing diagnoses in potentially healthy donor candidates.
- Author
-
Mühlbacher, Thomas, Nadalin, Silvio, Althaus, Karina, Birkenfeld, Andreas L., Heyne, Nils, and Guthoff, Martina
- Subjects
- *
KIDNEYS , *DIAGNOSIS , *ENDOCRINE diseases , *GASTROINTESTINAL diseases , *KIDNEY transplantation - Abstract
Background: In order to ensure eligibility for living kidney donation, donor candidates undergo a thorough medical evaluation. This process might reveal hitherto undetected medical conditions, leading to refusal of the kidney donor candidate. Detection of such conditions may, however, also have a lifesaving effect. We report on 13 years of data from our living donor transplantation program on kidney donor candidates who were diagnosed with major medical conditions during evaluation. Materials and methods: We performed a retrospective analysis of living kidney donor candidates who attended our transplant center between January, 2007 and December, 2019. The main focus was on newly diagnosed medical conditions that required immediate medical attention and their prognostic significance. Results: Of the 436 donor candidates who were evaluated for living kidney donation at our transplant center, 192 (44%) were accepted, while 244 (56%) were excluded from donation. Interestingly, 81 (33.1%) of the ineligible donor candidates were newly diagnosed as having a medical condition that required immediate attention. While 45 (18.5%) candidates were newly diagnosed with diabetes or prediabetes, 12 (4.9%) candidates had hitherto undetected malignancies, 10 candidates (4.1%) cardiac disease, five (2.0%) hypertension with end‐organ damage, and four (1.6%) suffered from kidney disease. The remaining four candidates (1.6%) were diagnosed with gastrointestinal diseases, and one candidate (.4%) had an endocrine disorder. Conclusion: A comprehensive evaluation process for living kidney donation facilitates the identification of life‐changing diagnoses in a significant proportion of candidates and secures immediate medical attention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay
- Author
-
Althaus, Karina, Strobel, Ulrike, Warkentin, Theodore E., and Greinacher, Andreas
- Subjects
- *
ENZYME-linked immunosorbent assay , *HEPARIN , *IMMUNOGLOBULINS , *BLOOD platelet activation , *DRUG efficacy , *SENSITIVITY analysis - Abstract
Abstract: Background: IgG-specific anti-PF4/heparin enzyme-immunoassays (EIAs) are sensitive but not specific for platelet-activating antibodies, the cause of heparin-induced thrombocytopenia (HIT). Two features of EIA reactivity predict for presence of HIT antibodies - the magnitude of a positive result (in optical density [OD] units) and the inhibition of reactivity at high heparin concentrations - but their combined utility remains uncertain. Objective: To determine for an IgG-specific EIA how the OD values of a positive reaction and its inhibition by high heparin can be optimally combined. Methods: We screened 1,000 consecutive patients with suspected HIT using an IgG-specific PF4/heparin in-house EIA with and without high heparin (100IU/mL); and by the heparin-induced platelet activation test. Results: Platelet-activating antibodies were rarely detected (<0.2%) when the IgG-specific EIA was negative at the conventional cut-off (OD, 0.5). However, an OD cut-off of 1.0 resulted in an unacceptable loss of sensitivity (14/83=17%) for detecting platelet-activating antibodies. The high heparin step increased specificity for platelet-activating antibodies from 72% to 89% without loss of sensitivity when applied to weak-positive sera (OD≤1.0). However, decreased sensitivity was observed with strong-positive sera (OD>1.0): 11/69 such sera (16%) that did not show >40% inhibition by high heparin nevertheless contained platelet-activating antibodies. Conclusion: Specificity of an IgG-specific EIA for detecting platelet-activating antibodies can be optimized by applying the high heparin inhibition step to weak-positive reactions (0.5-≤1.0 OD). However, applying the high heparin inhibition step to strong-positive reactions (>1.0 OD) in our in-house assay risks falsely classifying a serum as negative for platelet-activating antibodies. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
10. MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis.
- Author
-
Althaus, Karina and Greinacher, Andreas
- Subjects
- *
BLOOD platelet disorders , *EPSTEIN-Barr virus diseases , *THROMBOCYTOPENIA , *MYOSIN , *GRANULOCYTES , *GENETIC code , *CYTOSKELETAL proteins , *IMMUNOFLUORESCENCE - Abstract
MYH-9 related platelet disorders belong to the group of inherited giant platelet disorders. The MYH-9 gene encodes the non-muscular myosin heavy chain IIA (NMMHCIIA), a cytoskeletal contractile protein. Several mutations in the MYH-9 gene lead to macrothrombocytopenia, and cytoplasmic inclusion bodies within leukocytes, while the number of megakaryocytes in the bone marrow is normal. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. More than 30 mutations within the 40 exons of the MYH-9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid ∼1400 are more likely associated with syndromic manifestations than the downstream mutations. Diagnosis is based on identification of the granulocyte inclusion bodies using blood smears and immunofluorescence and is finally confirmed by identifying the mutation. Treatment is supportive and should be aimed to prevent iron deficiency anemia. Beside renal failure, the biggest risk for patients affected by a MYH-9 disorder are the adverse effects resulting form treatment based on the misdiagnosis of immune thrombocytopenia. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Characteristics Associated with COVID-19 Breakthrough Infections after Booster Vaccinations in Healthcare Workers: Insights from the TüSeRe:exact Study.
- Author
-
Uzun, Günalp, Bareiß, Alan, Becker, Matthias, Althaus, Karina, Dulovic, Alex, Junker, Daniel, Schenke-Layland, Katja, Martus, Peter, Borst, Oliver, Schneiderhan-Marra, Nicole, and Bakchoul, Tamam
- Subjects
- *
BREAKTHROUGH infections , *MEDICAL personnel , *BOOSTER vaccines , *COVID-19 , *CARDIOVASCULAR diseases - Abstract
Background: The prevalence of COVID-19 breakthrough infections in healthcare workers (HCWs) remains an issue of concern. This study examines the different characteristics associated with breakthrough infections in HCWs. Methods: From the total participants in the TüSeRe:exact study (n = 1046), we specifically included study participants who had received three vaccinations and were not infected prior to the third vaccination. Participants were invited to complete an online questionnaire, which included inquiries about any breakthrough infections they might have experienced. Univariate Cox regression analysis was used to investigate the association between participant characteristics and breakthrough infections. Results: Among 629 HCWs (497 female and 132 male), 241 (38%) experienced breakthrough infections during the follow-up period. The frequency of breakthrough infections was 39.2% (195/497) among female participants and 34.8% (46/132) among male participants (p = 0.357). The Cox regression model adjusted for age and sex showed that participants with cardiovascular disease (hazard ratio (95%CI) = 0.621 (0.392–0.985); p = 0.043) and those taking antihypertensives (hazard ratio (95%CI) = 0.551 (0.331–0.915); p = 0.021) had a significantly lower hazard ratio for breakthrough infections. The use of analgesics after the first vaccine (hazard ratio (95%CI) = 1.343 (1.025–1.759); p = 0.032) was associated with an increased risk of breakthrough infections. Conclusions: These findings can inform targeted preventive measures and risk management strategies to protect frontline workers and maintain a resilient healthcare system during the ongoing pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Platelet dysfunction caused by a novel thromboxane A2 receptor mutation and congenital thrombocytopenia in a case of mild bleeding.
- Author
-
Bugert, Peter, Fischer, Lars, Althaus, Karina, Knöfler, Ralf, and Bakchoul, Tamam
- Subjects
- *
BLOOD platelet disorders , *BLOOD platelets , *THROMBOCYTOPENIA , *CONGENITAL disorders , *PLATELET count , *HEMOPHILIA - Abstract
Chronic hemorrhagic diathesis in patients showing normal levels of plasmatic clotting factors strongly suggests for congenital platelet disorders. We report on a pediatric patient (male, 3 years, D1) with mild bleeding. A sibling (D2), his mother (D3) and father (D4) were included for laboratory investigation. Platelet counts in D1, D2 and D4 indicated mild thrombocytopenia (100 Gpt/L). D1 and D3 platelets showed significantly diminished aggregation response on arachidonic acid and U46619 stimulation. Immunostaining for platelet proteins on blood smears of D1 and D2 indicated defects in ß1-tubulin. Exon sequencing of TBXA2R and TUBB1 revealed heterozygosity for the novel TBXA2R*c.908T>C (p.L303P) mutation in D1 and D3. TUBB1 was either wild type (D2, D3) or heterozygous (D1, D4) for the common polymorphism TUBB1*c.920G>A (rs6070697; p.R307H). In conclusion, the bleeding phenotype of the index patient can be explained by a diminished platelet function caused by the TBXA2R*c.908T>C mutation inherited from the mother and a mild thrombocytopenia with unknown molecular basis that is inherited from the father. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Membrane oxygenator longevity was higher in argatroban‐treated patients undergoing vvECMO.
- Author
-
Menninger, Loredana, Körner, Andreas, Mirakaj, Valbona, Heck‐Swain, Ka‐Lin, Haeberle, Helene A., Althaus, Karina, Baumgaertner, Michael, Jost, Walter, Schlensak, Christian, Rosenberger, Peter, and Koeppen, Michael
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *OXYGENATORS , *ADULT respiratory distress syndrome , *ERYTHROCYTES , *PLASMA products , *INTENSIVE care units - Abstract
Background: In severe acute respiratory distress syndrome (ARDS), venovenous extracorporeal membrane oxygenation (vvECMO) can be a lifesaver. However, anticoagulation therapy is mandatory because the nonendothelial extracorporeal surface increases the risk of thromboembolic problems. Heparin is still the most common anticoagulant, but argatroban could be an alternative. This work investigates whether argatroban offers a therapeutic advantage over heparin during vvECMO. Methods: We performed a retrospective cohort study of patients who underwent vvECMO for severe ARDS and received heparin or argatroban as anticoagulation therapy. Demographic variables, intensive care unit (ICU) treatment and outcome parameters were evaluated. The primary outcome parameter was the operating time of the membrane oxygenator normalized to the duration of vvECMO treatment. Secondary outcome parameters were transfusion requirements normalized to the duration of vvECMO therapy. Results: Fifty seven patients from January 2019 to February 2021 underwent vvECMO and were included in this study. Thirty three patients received heparin and 24 patients argatroban as anticoagulatory therapy. The groups did not differ in demographics, ICU scoring systems, or comorbidities. Platelet counts and partial prothrombin time did not differ between the two groups during the first 6 days of vvECMO. The argatroban group had lower requirements for red blood cells, platelets and fresh frozen plasma. The mean runtime of the individual membrane oxygenator increased from 12.3 days (heparin group) to 16.6 days in the argatroban group. Conclusions: Our findings suggest that argatroban can be considered as anticoagulant during vvECMO. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Uterine allograft removal by total laparoscopic hysterectomy after successful cesarean delivery in a living-donor uterus recipient with uterovaginal agenesis (MRKHS).
- Author
-
Brucker, Sara Yvonne, Krämer, Bernhard, Abele, Harald, Henes, Melanie, Hoopmann, Markus, Schöller, Dorit, Königsrainer, Alfred, Bösmüller, Hans, Nikolaou, Konstantin, Krumm, Patrick, Rosenberger, Peter, Heim, Eckhard, Amend, Bastian, Rausch, Steffen, Althaus, Karina, Bakchoul, Tamam, Guthoff, Martina, Heyne, Nils, Nadalin, Silvio, and Rall, Kristin Katharina
- Subjects
- *
CESAREAN section , *VAGINOPLASTY , *UTERUS , *HOMOGRAFTS , *HYSTERECTOMY , *SURGICAL complications - Abstract
Purpose: To limit the burden of long-term immunosuppression (IS) after uterus transplantation (UTx), removal of the uterine allograft is indicated after maximum two pregnancies. Hitherto this has required graft hysterectomy by laparotomy. Our objective was to demonstrate, as a proof of concept, the feasibility of less traumatic transplantectomy by total laparoscopic hysterectomy (TLH). Patient: A 37-year-old woman with uterovaginal agenesis due to Mayer–Rokitansky–Küster–Hauser syndrome (MRKHS) who had undergone neovaginoplasty at age 19 years prior to living-donor (LD) UTx in 10/2019 at age 35 years gave birth to a healthy boy by primary cesarean section in 06/2021. During pregnancy, she developed impaired renal function, with bilateral hydronephrosis, necessitating early allograft removal in 09/2021 to prevent chronic kidney disease, particularly during a potential second pregnancy. Methods: Transplantectomy by TLH essentially followed standard TLH procedures. We paid meticulous attention to removing as much donor tissue as possible to prevent postoperative complications from residual donor tissue after stopping IS, as well as long-term vascular damage. Results: TLH was performed successfully without the need to convert to open surgery. Surgical time was 90 min with minimal blood loss. No major complications occurred intra- or postoperatively and during the subsequent 9-month follow-up period. Kidney function normalized. Conclusions: To our knowledge, we report the first successful TLH-based removal of a uterine allograft in a primipara after LD UTx, thus demonstrating the feasibility of TLH in uterus recipients with MRKHS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants.
- Author
-
Junker, Daniel, Becker, Matthias, Wagner, Teresa R, Kaiser, Philipp D, Maier, Sandra, Grimm, Tanja M, Griesbaum, Johanna, Marsall, Patrick, Gruber, Jens, Traenkle, Bjoern, Heinzel, Constanze, Pinilla, Yudi T, Held, Jana, Fendel, Rolf, Kreidenweiss, Andrea, Nelde, Annika, Maringer, Yacine, Schroeder, Sarah, Walz, Juliane S, and Althaus, Karina
- Subjects
- *
BINDING sites , *INTERFEROMETRY , *STATISTICS , *COVID-19 , *COVID-19 treatment , *VIRAL proteins , *COVID-19 vaccines , *SERUM , *LIQUID chromatography , *MANN Whitney U Test , *IMMUNOASSAY , *MASS spectrometry , *DESCRIPTIVE statistics , *RESEARCH funding , *VIRAL antibodies , *SEROTHERAPY , *VACCINATION status , *DATA analysis software , *STATISTICAL correlation , *DATA analysis , *ANGIOTENSIN converting enzyme - Abstract
Background The rapid emergence of the Omicron variant and its large number of mutations led to its classification as a variant of concern (VOC) by the World Health Organization. Subsequently, Omicron evolved into distinct sublineages (eg, BA.1 and BA.2), which currently represent the majority of global infections. Initial studies of the neutralizing response toward BA.1 in convalescent and vaccinated individuals showed a substantial reduction. Methods We assessed antibody (immunoglobulin G [IgG]) binding, ACE2 (angiotensin-converting enzyme 2) binding inhibition, and IgG binding dynamics for the Omicron BA.1 and BA.2 variants compared to a panel of VOCs/variants of interest, in a large cohort (N = 352) of convalescent, vaccinated, and infected and subsequently vaccinated individuals. Results While Omicron was capable of efficiently binding to ACE2, antibodies elicited by infection or immunization showed reduced binding capacities and ACE2 binding inhibition compared to wild type. Whereas BA.1 exhibited less IgG binding compared to BA.2, BA.2 showed reduced inhibition of ACE2 binding. Among vaccinated samples, antibody binding to Omicron only improved after administration of a third dose. Conclusions Omicron BA.1 and BA.2 can still efficiently bind to ACE2, while vaccine/infection-derived antibodies can bind to Omicron. The extent of the mutations within both variants prevents a strong inhibitory binding response. As a result, both Omicron variants are able to evade control by preexisting antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia
- Author
-
Althaus, Karina, Hron, Gregor, Strobel, Ulrike, Abbate, Rosanna, Rogolino, Angela, Davidson, Simon, Greinacher, Andreas, and Bakchoul, Tamam
- Subjects
- *
IMMUNOASSAY , *HEPARIN , *THROMBOCYTOPENIA , *PLATELET activating factor , *IMMUNOGLOBULINS , *PLATELET factor 4 , *CHEMILUMINESCENCE - Abstract
Abstract: Background: Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize platelet factor 4/heparin (PF4/hep) complexes. The in vitro demonstration of PF4/hep antibodies using functional and immunological methods is essential for optimal management of patients suspected to have HIT. Since functional assays are technically challenging and limited to specialized laboratories, antigen-binding assays are commonly used in routine laboratories. Study Design: Blood samples from 448 consecutive patients in whom HIT was suspected were investigated using a latex agglutination test HemosIL® HIT-Ab(PF4-H) (HemosIL-Ab), two chemiluminescence tests HemosIL AcuStar HIT-Ab(PF4-H) (HemosIL AcuStar-Ab) and AcuStar HIT-IgG(PF4-H) (HemosIL AcuStar-IgG), an in-house PF4/hep IgG enzyme immunoassay (EIA) and the heparin induced platelet aggregation (HIPA) test. Results: Antibodies against PF4/hep were detectable in 44 out of 119 samples using HemosIL-Ab among which 20 samples were also reactive in the HIPA; and in 122, 64 and 108 out of 448 sera using HemosIL AcuStar-Ab, HemosIL AcuStar-IgG and in-house PF4/hep IgG-EIA, respectively, among which 52 sera were also reactive in the HIPA. All assays had high sensitivities of >95% for platelet activating antibodies; however, they differed in their specificities. The highest specificity and positive predictive value was observed by HemosIL AcuStar-IgG (96% and 78%, respectively). Conclusion: Automated immunoassays are useful in the laboratory investigations of HIT and present a potential improvement toward standardization of laboratory investigations of HIT. The high positive predictive capability may justify treating the patient with alternative anticoagulants without waiting for the results of a functional assay. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
17. Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.
- Author
-
Bareiß, Alan, Uzun, Günalp, Mikus, Marco, Becker, Matthias, Althaus, Karina, Schneiderhan-Marra, Nicole, Fürstberger, Axel, Schwab, Julian D., Kestler, Hans A., Holderried, Martin, Martus, Peter, Schenke-Layland, Katja, and Bakchoul, Tamam
- Subjects
- *
MEDICAL personnel , *VACCINATION complications , *BOOSTER vaccines , *VACCINATION , *HEALTH facilities - Abstract
As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during the TüSeRe: exact study (Tübinger Monitoring Studie zur exakten Analyse der Immunantwort nach Vakzinierung). Employees of health and research institutions were invited to participate. Study participants were asked to fill out an online questionnaire and report their SE after each dose of SARS-CoV-2 vaccination. A total of 1046 participants (mean age: 44 ± 12.9 years; female, n = 815 (78%); male, n = 231 (22%)) were included in the analysis. Local and systemic SE were more frequent after receiving the vector-based vaccine ChAdOx1 nCoV-19 in the first vaccination. However, local and systemic SE were more common after receiving mRNA vaccines (BNT162b2, mRNA-1273) in the second vaccination. Compared to the BNT162b2 vaccine, more SE have been observed after receiving the mRNA-1273 vaccine in the booster vaccination. In multivariate analysis, local and systemic side effects were associated with vaccine type, age and gender. Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE differ significantly between mRNA and vector-based vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants.
- Author
-
Junker, Daniel, Dulovic, Alex, Becker, Matthias, Wagner, Teresa R., Kaiser, Philipp D., Traenkle, Bjoern, Kienzle, Katharina, Bunk, Stefanie, Struemper, Carlotta, Haeberle, Helene, Schmauder, Kristina, Ruetalo, Natalia, Malek, Nisar, Althaus, Karina, Koeppen, Michael, Rothbauer, Ulrich, Walz, Juliane S., Schindler, Michael, Bitzer, Michael, and Göpel, Siri
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *NEUTRALIZATION tests , *ANGIOTENSIN converting enzyme , *IMMUNOGLOBULINS , *ENDOCYTOSIS , *VIRAL antibodies - Abstract
As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising correlates of protective immunity and have been successfully used for prevention and therapy. As SARS-CoV-2 variants of concern (VOCs) are known to affect binding to the ACE2 receptor and by extension neutralizing activity, we developed a bead-based multiplex ACE2-RBD inhibition assay (RBDCoV-ACE2) as a highly scalable, time-, cost-, and material-saving alternative to infectious live-virus neutralization tests. By mimicking the interaction between ACE2 and the RBD, this serological multiplex assay allows the simultaneous analysis of ACE2 binding inhibition to the RBDs of all SARS-CoV-2 VOCs and variants of interest (VOIs) in a single well. Following validation against a classical virus neutralization test and comparison of performance against a commercially available assay, we analyzed 266 serum samples from 168 COVID-19 patients of varying severity. ACE2 binding inhibition was reduced for ten out of eleven variants examined compared to wild-type, especially for those displaying the E484K mutation such as VOCs beta and gamma. ACE2 binding inhibition, while highly individualistic, positively correlated with IgG levels. ACE2 binding inhibition also correlated with disease severity up to WHO grade 7, after which it reduced. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Blood donor‐derived buffy coat to produce platelets in vitro.
- Author
-
Marini, Irene, Rigoni, Flavianna, Zlamal, Jan, Pelzl, Lisann, Althaus, Karina, Nowak‐Harnau, Stefanie, Rondina, Matthew T., and Bakchoul, Tamam
- Subjects
- *
BLOOD platelets , *PROGENITOR cells , *BLOOD cells , *BLOOD , *BLOOD platelet transfusion - Abstract
Background and objectives: Platelet transfusion is a standard medical therapy used to treat several bleeding disorders. However, a critical drawback is the dependency on donor‐derived platelets, which leads to concerns like insufficient availability and immunological complications. In vitro platelet production from hematopoietic progenitor cells (CD34) may represent a reasonable solution. Materials and methods: CD34+ cells were isolated from either buffy coat or peripheral blood and compared in terms of platelet production in vitro. The number and the quality of magnetically isolated CD34+ cells and their capability to differentiate into mature megakaryocytes were investigated using flow cytometry. Additionally, the functionality of megakaryocytes in term of in vitro platelet production was tested. Results: Similar purity and quantity of CD34+ cells was found after their isolation from both cell sources. In contrast, after 6 days of culture, enhanced number of CD34+ cells isolated from buffy coat compared with peripheral blood was observed (5·3 x 106 vs. 3·0 x 106, respectively). Interestingly, despite a comparable nuclear maturation phenotype, the yield of platelets released from buffy coat‐derived megakaryocytes was significantly higher than from peripheral blood cells (platelet yield pro MK: 7·2 vs. 2·7, respectively). Importantly, platelets produced from buffy coat‐derived cells could be activated by agonists. Conclusion: Haematopoietic progenitor cells isolated from buffy coat have increased yield of platelets released from mature megakaryocytes and enhanced in vitro functionality, compared with peripheral blood‐derived cells. Our study, suggests that buffy coat, obtained during blood donation processing, might be a promising source of megakaryocytes for in vitro platelet production. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting.
- Author
-
Revel-Vilk, Shoshana, Shai, Ela, Turro, Ernest, Jahshan, Nivin, Hi-Am, Esti, Spectre, Galia, Daum, Hagit, Kalish, Yossef, Althaus, Karina, Greinacher, Andreas, Kaplinsky, Chaim, Izraeli, Shai, Mapeta, Rutendo, Deevi, Sri V. V., Jarocha, Danuta, Ouwehand, Willem H., Downes, Kate, Poncz, Mortimer, Varon, David, and Lambert, Michele P.
- Subjects
- *
BLOOD platelet disorders , *GENES , *PLATELET count , *THROMBOCYTOPENIA , *SIALIC acids - Abstract
The article offers insight to a study conducted for analyzing glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase (GNE) variants causing autosomal recessive macrothrombocytopenia. It mentions about laboratory evidence supporting pathogenicity for the identified variants and mechanism for thrombocytopenia; N-acetylneuraminic acid–containing pentasaccharide sialic acid; and role for platelet sialylation in regulation of platelet count.
- Published
- 2018
- Full Text
- View/download PDF
21. Evaluation of a diagnostic algorithm for Heparin-Induced Thrombocytopenia.
- Author
-
Farm, Maria, Bakchoul, Tamam, Frisk, Tony, Althaus, Karina, Odenrick, Alice, Norberg, Eva-Marie, Berndtsson, Maria, and Antovic, Jovan P.
- Subjects
- *
THROMBOCYTOPENIA treatment , *HEPARIN , *PROTHROMBIN , *BLOOD platelet activation , *IMMUNOGLOBULIN G - Abstract
Introduction Heparin-Induced Thrombocytopenia (HIT) is a rare but serious immune-mediated complication of heparin treatment. HIT is characterized by an acute, transient prothrombotic state combined with thrombocytopenia and is caused by platelet-activating IgG antibodies that bind to complexes of heparin and platelet factor 4. The diagnosis of HIT relies on clinical presentation and the demonstration of HIT antibodies. One approach to improve the efficacy of laboratory analysis is to use a diagnostic algorithm. Aim To evaluate one diagnostic algorithm for HIT where the 4 T's clinical risk score is combined with immunochemical and/or functional assays. Materials and methods The quality of the diagnostic algorithm was retrospectively evaluated in 101 patients with suspected HIT. Laboratory results obtained from the diagnostic algorithm were compared to Heparin-Induced Platelet Aggregation (HIPA) and clinico-pathological evaluation of patients' medical records. Results We found that the algorithm had a diagnostic efficacy of 94%, with specificity of 94% and sensitivity 94%. Positive likelihood ratio (LR +) was 16.0, and the negative likelihood ratio (LR −) 15.5. The efficacy of PaGIA ( n = 95) was 0.46, and IgG-specific HPF4-abELISA ( n = 54) was 0.87. Conclusions The diagnostic algorithm for HIT is sufficiently accurate and leads to in overall faster results and decreased cost of analysis. The weakest link of the algorithm is the risk of miscalculated 4 T's scores, which is inevitably exacerbated by the insufficient experience most clinicians have with HIT. This highlights the importance of clear instructions from the laboratory and coagulation clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test.
- Author
-
Hron, Gregor, Knutson, Folke, Thiele, Thomas, Althaus, Karina, Busemann, Christoph, Friesecke, Sigrun, Greinacher, Andreas, and Lubenow, Norbert
- Abstract
Thrombocytopenia can cause diagnostic challenges in patients who have received heparin. Heparin-induced thrombocytopenia (HIT) is often considered in the differential diagnosis, and a positive screening can be mistaken as confirmation of the disorder. We present two patients who both received low-molecular-weight heparin for several days. In the first patient, clinical judgment rejected the suspicion of HIT despite a positive screening assay, and treatment for the alternative diagnosis of post-transfusion purpura was correctly initiated. In the second patient, the inaccurate diagnosis HIT was pursued due to a positive screening assay, while the alternative diagnosis of drug-dependent thrombocytopenia caused by piperacillin/tazobactam was rejected. This resulted in re-exposure to piperacillin/tazobactam which caused a second episode of severe thrombocytopenia. A positive screening assay for platelet factor 4/heparin-antibody should be verified by a functional assay, especially in patients with low pretest probability for HIT. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.